Nautilus Biotechnology, Inc. (NAUT)

Market Cap	322.70M
Revenue (ttm)	n/a
Net Income (ttm)	-70.21M
Shares Out	125.56M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,954
Open	2.590
Previous Close	2.610
Day's Range	2.460 - 2.660
52-Week Range	2.190 - 3.455
Beta	1.04
Analysts	Buy
Price Target	4.50 (+75.1%)
Earnings Date	Oct 29, 2024

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 167
• Stock Exchange: NASDAQ
• Ticker Symbol: NAUT
• Website: https://www.nautilus.bio

Analyst Forecast

According to 2 analysts, the average rating for NAUT stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 75.10% from the latest price.

Price Target

$4.5

(75.10% upside)

Analyst Consensus: Buy